Pharmacology of Antisense Drugs

Annual Review of Pharmacology and Toxicology

Volumn 57, Issue , 2017, Pages 81-105

  Bennett, C Frank ^a   Baker, Brenda F ^a   Pham, Nguyen ^a   Swayze, Eric ^a   Geary, Richard S ^a  

^a ISIS PHARMACEUTICALS   (United States)

Author keywords

antisense oligonucleotides; eteplirsen; mipomersen; nusinersen; oligonucleotide; patisiran; RNA; RNA interference; RNA splicing RNase H

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; DRISAPERSEN; ETEPLIRSEN; HETEROCYCLIC COMPOUND; MIPOMERSEN; RG 101; RNA; SUGAR; UNCLASSIFIED DRUG;

AUTOIMMUNE DISEASE; BINDING AFFINITY; CARDIOVASCULAR DISEASE; CELL FUNCTION; CHEMICAL MODIFICATION; CONJUGATION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; HUMAN; INFECTION; INFLAMMATION; MALIGNANT NEOPLASM; MEDICINAL CHEMISTRY; NEUROLOGIC DISEASE; NONHUMAN; PHARMACOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLASMA PROTEIN BINDING; PRIORITY JOURNAL; REVIEW; RNA BINDING; RNA HYBRIDIZATION; ANIMAL; DRUG EFFECTS; METABOLISM; PHYSIOLOGY; RNA INTERFERENCE; RNA SPLICING;

ANIMALS; AUTOIMMUNE DISEASES; CARDIOVASCULAR DISEASES; HUMANS; OLIGONUCLEOTIDES, ANTISENSE; RNA INTERFERENCE; RNA SPLICING;

EID: 85009064500     PISSN: 03621642     EISSN: 15454304     Source Type: Book Series    
DOI: 10.1146/annurev-pharmtox-010716-104846     Document Type: Review

References (142)

1. Rader DJ, Kastelein JJ. 2014. Lomitapide and mipomersen: two first-in-class drugs for reducing lowdensity lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia. Circulation 129:1022-32
2. Bennett CF, Swayze EE. 2010.RNA targeting therapeutics:molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Ann. Rev. Pharmacol. Toxicol. 50:259-93
3. Bennett CF, Swayze E, Henry S, Geary R. 2015. Antisense oligonucleotide-based therapeutics. In Gene and Cell Therapy: Therapeutic Mechanisms and Strategies, ed. NS Templeton, pp. 467-92. Boca Raton, FL: CRC Press
4. Akinc A, Betterncourt BR, Maier MA. 2015. Development of RNAi therapeutics. In Gene and Cell Therapy: Therapeutic Mechanisms and Strategies, ed. NS Templeton, pp. 493-520. Boca Raton, FL: CRC Press
5. Soto-Pantoja DR, Isenberg JS, Roberts DD. 2015. Therapeutic applications of morpholino oligonucleotides. In Gene and Cell Therapy: Therapeutic Mechanisms and Strategies, ed. NS Templeton, pp. 521-41. Boca Raton, FL: CRC Press
6. Lima WF, Wu H, Crooke ST. 2008. The RNase H mechanism. In Antisense Drug Technology: Principles, Strategies, and Applications, ed. ST Crooke, pp. 47-74. Boca Raton, FL: CRC Press
7. Esau C, Davis S, Murray SF, Yu XX, Pandey SK, et al. 2006. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab. 3:87-98
8. Rotllan N, Raḿrez CM, Aryal B, Esau CC, Fernández-Hernando C. 2013. Therapeutic silencing of microRNA-33 inhibits the progression of atherosclerosis in Ldlr/mice-brief report. Arterioscler. Thromb. Vasc. Biol. 33:1973-77
9. Liang X-H, Shen W, Sun H, Migawa MT, Vickers TA, Crooker ST. 2016. Translation efficiency of mRNAs is increased by antisense oligonucleotides targeting upstream open reading frames. Nat. Biotechnol. 34:875-880
10. SteinCA, Subasinghe C, Shinozuka K, Cohen JS. 1988. Physicochemical properties of phosphorothioate oligodeoxynucleotides. Nucleic Acids Res. 16:3209-21
11. Gryaznov S, Skorski T, Cucco C, Nieborowska-Skorska M, Chiu CY, et al. 1996. Oligonucleotide N3-P5-phosphoramidates as antisense agents. Nucleic Acids Res. 24:1508-14
12. Herdewijn P. 2000. Heterocyclic modifications of oligonucleotides and antisense technology. Antisense Nucleic Acid Drug Dev. 10:297-310
13. Freier SM, Altmann K-H. 1997. The ups and downs of nucleic acid duplex stability: structure-stability studies on chemically-modified DNA:RNA duplexes. Nucleic Acids Res. 25:4429-43
14. Krieg AM, Yi AK, Matson S, Waldschmidt TJ, Bishop GA, et al. 1995. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374:546-49
15. Froehler BC, Wadwani S, Terhorst TJ, Gerrard SR. 1992. Oligodeoxynucleotides containing C-5 propyne analogs of 2-deoxyuridine and 2-deoxycytidine. Tetrahedron Lett. 33:5307-10
16. Shen L, Siwkowski A, Wancewicz EV, Lesnik EA, Butler M, et al. 2003. Evaluation of C-5 propynyl pyrmidine-containing oligonucleotides in vitro and in vivo. Antisense Nucleic Acid Drug Dev. 13:129-42
17. Monia BP, Lesnik EA, Gonzalez C, LimaWF, McGeeD, et al. 1993. Evaluation of 2-modified oligonucleotides containing 2-deoxy gaps as antisense inhibitors of gene expression. J. Biol. Chem. 268:14514-22
18. Goel S, Desai K, Macapinlac M, Wadler S, Goldberg G, et al. 2006. A phase I safety and dose escalation trial of docetaxel combined with GEMR-231, a second generation antisense oligonucleotide targeting protein kinase A R1in patients with advanced solid cancers. Investig. New Drugs 24:125-34
19. Voit T, Topaloglu H, Straub V, Muntoni F, Deconinck N, et al. 2014. Safety and efficacy of drisapersen for the treatment ofDuchenne muscular dystrophy (DEMANDII): an exploratory, randomised, placebocontrolled phase 2 study. Lancet Neurol. 13:987-96
20. Soutschek J, Akinc A, Bramlage B, Charisse K, Constien R, et al. 2004. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432:173-78
21. ZimmermannTS, Lee AC, Akinc A, Bramlage B, Bumcrot D, et al. 2006. RNAi-mediated gene silencing in non-human primates. Nature 441:111-14
22. Jackson AL, Burchard J, Leake D, Reynolds A, Schelter J, et al. 2006. Position-specific chemical modification of siRNAs reduces "off-target" transcript silencing. RNA 12:1197-205
23. Allerson CR, Sioufi N, Jarres R, Prakash TP, Naik N, et al. 2005. Fully 2-modified oligonucleotide duplexes with improved in vitro potency and stability compared to unmodified small interfering RNA. J. Med. Chem. 48:901-4
24. Nair JK, Willoughby JLS, Chan A, Charisse K, Alam MR, et al. 2014. MultivalentN-acetylgalactosamineconjugated siRNAlocalizes in hepatocytes and elicits robust RNAi-mediated gene silencing. J. Am.Chem. Soc. 136:16958-61
25. Henry S, Stecker K, Brooks D, Monteith D, Conklin B, Bennett CF. 2000. Chemically modified oligonucleotides exhibit decreased immune stimulation in mice. J. Pharmacol. Exp. Ther. 292:468-79
26. Crooke ST, Geary RS. 2013. Clinical pharmacological properties of mipomersen (Kynamro), a second generation antisense inhibitor of apolipoprotein B. Br. J. Clin. Pharmacol. 76:269-76
27. Chiriboga CA, Swoboda KJ, Darras BT, Iannaccone ST, Montes J, et al. 2016. Results from a phase 1 study of nusinersen (ISIS-SMNRx) in children with spinal muscular atrophy. Neurology 86:890-97
28. Rigo F, Chun SJ, Norris DA, Hung G, Lee S, et al. 2014. Pharmacology of a central nervous system delivered 2-O-methoxyethyl-modified survival of motor neuron splicing oligonucleotide in mice and nonhuman primates. J. Pharmacol. Exp. Ther. 350:46-55
29. Ackermann EJ, Guo S, BensonMD, Booten S, Freier S, et al. 2016. Suppressing transthyretin production in mice, monkeys and humans using 2nd-generation antisense oligonucleotides. Amyloid. 23:148-57
30. Lima WF, Prakash TP, Murray HM, Kinberger GA, Li W, et al. 2012. Single-stranded siRNAs activate RNAi in animals. Cell 150:883-94
31. Obika S, Nanbu D, Hari Y, Morio K-I, In Y, et al. 1997. Synthesis of 2-O,4-C-methyleneuridine and-cytidine. Novel bicyclic nucleosides having a fixed C3,-endo sugar puckering. Tetrahedron Lett. 38:8735-38
32. Wengel J. 1999. Synthesis of 3-C-and 4-C-branched oligodeoxynucleotides and the development of locked nucleic acid (LNA). Acc. Chem. Res. 32:301-10
33. Kurreck J, Wyszko E, Gillen C, Erdmann VA. 2002. Design of antisense oligonucleotides stabilized by locked nucleic acids. Nucleic Acids Res. 30:1911-18
34. Seth PP, Swayze EE. 2014. Unnatural nucleoside analogs for antisense therapy. In Natural Products in Medicinal Chemistry, ed. S Hanessian, pp. 403-40. Weinheim, Ger.: Wiley-VCH
35. Fluiter K, Frieden M, Vreijling J, Rosenbohm C, De Wissel MB, et al. 2005. On the in vitro and in vivo properties of four locked nucleic acid nucleotides incorporated into an anti-H-Ras antisense oligonucleotide. ChemBioChem 6:1104-9
36. Morita K, Hasegawa C, Kaneko M, Tsutsumi S, Sone J, et al. 2002. 2-O,4-C-ethylene-bridged nucleic acids (ENA): highly nuclease-resistant and thermodynamically stable oligonucleotides for antisense drug. Bioorg. Med. Chem. Lett. 12:73-76
37. Burdick AD, Sciabola S, Mantena SR, Hollingshead BD, Stanton R, et al. 2014. Sequence motifs associated with hepatotoxicity of locked nucleic acid-modified antisense oligonucleotides. Nucleic Acids Res. 42:4882-489
38. Swayze EE, Siwkowski AM, Wancewicz EV, Migawa MT, Wyrzykiewicz TK, et al. 2007. Antisense oligonucleotides containing locked nucleic acid (LNA) improve potency but cause significant hepatotoxicity in animals. Nucleic Acids Res. 35:687-700
39. Prakash TP, Siwkowski A, Allerson CR, Migawa MT, Lee S, et al. 2010. Antisense oligonucleotides containing conformationally constrained 2-,4-(N-methoxy)aminomethylene and 2-,4-aminooxymethylene and 2-O,4-C-aminomethylene bridged nucleoside analogues show improved potency in animal models. J. Med. Chem. 53:1636-50
40. Seth PP, Jazayeri A, Yu J, Allerson CR, Bhat B, Swayze EE. 2012. Structure activity relationships of-L-LNA modified phosphorothioate gapmer antisense oligonucleotides in animals. Mol. Ther. Nucleic Acids 1:e47
41. Pallan PS, Allerson CR, Berdeja A, Seth PP, Swayze EE, et al. 2012. Structure and nuclease resistance of 2-,4-constrained 2-O-methoxyethyl (cMOE) and 2-O-ethyl (cEt) modified DNAs. Chem. Commun. 48:8195-97
42. Egli M, Pallan PS, Allerson CR, Prakash TP, Berdeja A, et al. 2011. Synthesis, improved antisense activity and structural rationale for the divergent RNA affinities of 3-fluoro hexitol nucleic acid (FHNA and Ara-FHNA) modified oligonucleotides. J. Am. Chem. Soc. 133:16642-49
43. Seth PP, Allerson CR, Siwkowski A, Vasquez G, Berdeja A, et al. 2010. Configuration of the 5-methyl group modulates the biophysical and biological properties of locked nucleic acid (LNA) oligonucleotides. J. Med. Chem. 53:8309-18
44. Burel SA, Han SR, Lee HS, Norris DA, Lee BS, et al. 2013. Preclinical evaluation of the toxicological effects of a novel constrained ethylmodified antisense compound targeting signal transducer and activator of transcription 3 in mice and cynomolgus monkeys. Nucleic Acid Ther. 23:213-27
45. Pandey SK, Wheeler TM, Justice SL, Kim A, Younis H, et al. 2015. Identification and characterization of modified antisense oligonucleotides targeting DMPK in mice and nonhuman primates for the treatment of myotonic dystrophy type 1. J. Pharmacol. Exp. Ther. 355:329-40
46. Crooke ST, Graham MJ, Zuckerman JE, BrooksD, Conklin BS, et al. 1996. Pharmacokinetic properties of several novel oligonucleotide analogs in mice. J. Pharmacol. Exp. Ther. 277:923-37
47. Krutzfeldt J, Rajewsky N, Braich R, Rajeev KG, Tuschl T, et al. 2005. Silencing of microRNAs in vivo with "antagomirs." Nature 438:685-89
48. Herbert BS, Gellert GC, Hochreiter A, Pongracz K, Wright WE, et al. 2005. Lipid modification of GRN163, an N3-P5-thio-phosphoramidate oligonucleotide, enhances the potency of telomerase inhibition. Oncogene 24:5262-68
49. Nishina K, Unno T, Uno Y, Kubodera T, Kanouchi T, et al. 2008. Efficient in vivo delivery of siRNA to the liver by conjugation of-tocopherol. Mol. Ther. 16:734-40
50. Nishina K, Piao W, Yoshida-Tanaka K, Sujino Y, Nishina T, et al. 2015. DNA/RNA heteroduplex oligonucleotide for highly efficient gene silencing. Nat. Commun. 6:7969
51. Prakash TP, Graham MJ, Yu J, Carty R, Low A, et al. 2014. Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice. Nucleic Acids Res. 42:8796-807
52. Prakash TP, Yu J, Migawa MT, Kinberger GA, WanWB, et al. 2016. Comprehensive structure-activity relationship of triantennary N-acetylgalactosamine conjugated antisense oligonucleotides for targeted delivery to hepatocytes. J. Med. Chem. 59:2718-33
53. Geary RS, Norris D, Yu R, Bennett CF. 2015. Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides. Adv. Drug Deliv. Rev. 87:46-51
54. Levin AA, Yu RZ, Geary RS. 2008. Basic principles of the pharmacokinetics of antisense oligonucleotide drugs. In Antisense Drug Technology: Principles, Strategies, and Applications, ed. ST Crooke, pp. 183-216. Boca Raton, FL: CRC Press
55. Koller E, Vincent TM, Chappell A, De S, Manoharan M, Bennett CF. 2011. Mechanisms of singlestranded phosphorothioate modified antisense oligonucleotide accumulation in hepatocytes. Nucleic Acids Res. 39:4795-807
56. Kordasiewicz HB, StanekLM, Wancewicz EV, MazurC, McAlonis MM, et al. 2012. Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis. Neuron 74:1031-44
57. Yu RZ, Lemonidis KM, Graham MJ, Matson JE, Crooke RM, et al. 2009. Cross-species comparison of in vivo PK/PD relationships for second-generation antisense oligonucleotides targeting apolipoprotein B-100. Biochem. Pharmacol. 77:910-19
58. Hung G, Xiao X, Peralta R, Bhattacharjee G, Murray S, et al. 2013. Characterization of target mRNA reduction through in situ RNA hybridization in multiple organ systems following systemic antisense treatment in animals. Nucleic Acid Ther. 23:369-78
59. Raoof AA, Chiu P, Ramtoola Z, Cumming IK, Teng CL, et al. 2004. Oral bioavailability and multiple dose tolerability of an antisense oligonucleotide tablet formulated with sodium caprate. J. Pharm. Sci. 93:1431-39
60. Templin MV, Levin AA, Graham MJ, Aberg PM, Axelsson BI, et al. 2000. Pharmacokinetic and toxicity profile of a phosphorothioate oligonucleotide following inhalation delivery to lung in mice. Antisense Nucleic Acid Drug Dev. 10:359-68
61. Miner PB Jr., Wedel MK, Xia S, Baker BF, Geary RS, Matson J. 2006. Bioavailability and therapeutic activity of alicaforsen (ISIS 2302) administered as a rectal retention enema to subjects with active ulcerative colitis. Aliment. Pharmacol. Ther. 23:1427-34
62. Tillman LG, Geary RS, Hardee GE. 2008. Oral delivery of antisense oligonucleotides in man. J. Pharm. Sci. 97:225-36
63. Iversen PL. 2008. Morpholinos. In Antisense Drug Technology: Principles, Strategies, and Applications, ed. ST Crooke, pp. 565-82. Boca Raton, FL: CRC Press
64. McMahon BM, Mays D, Lipsky J, Stewart JA, Fauq A, Richelson E. 2002. Pharmacokinetics and tissue distribution of a peptide nucleic acid after intravenous administration. Antisense Nucleic Acid Drug Dev. 12:65-73
65. Solano EC, Kornbrust DJ, Beaudry A, Foy JW, Schneider DJ, Thompson JD. 2014. Toxicological and pharmacokinetic properties of QPI-1007, a chemically modified synthetic siRNA targeting caspase 2 mRNA, following intravitreal injection. Nucleic Acid Ther. 24:258-66
66. Henry SP, Kim T-W, Kramer-Strickland K, Zanardi TA, Fey RA, Levin AA. 2008. Toxicological properties of 2-O-methoxyethyl chimeric antisense inhibitors in animals and man. In Antisense Drug Technology: Principles, Strategies, and Applications, ed. ST Crooke, pp. 327-63. Boca Raton, FL: CRC Press
67. Levin AA, Henry SP, Monteith D, Templin MV. 2001. Toxicity of antisense oligonucleotides. In Antisense Drug Technology: Principles, Strategies, and Applications, ed. ST Crooke, pp. 201-67. New York: Marcel Dekker. 1st ed
68. Castanotto D, Rossi JJ. 2009. The promises and pitfalls of RNA-interference-based therapeutics. Nature 457:426-33
69. Burel SA, Hart CE, Cauntay P, Hsiao J, Machemer T, et al. 2016. Hepatotoxicity of high affinity gapmer antisense oligonucleotides is mediated by RNase H1 dependent promiscuous reduction of very long pre-mRNA transcripts. Nucleic Acids Res. 44:2093-109
70. Henry SP, Seguin R, Cavagnaro J, Berman C, Tepper J, Kornbrust D. 2016. Considerations for the characterization and interpretation of results related to alternative complement activation in monkeys associated with oligonucleotide-based therapeutics. Nucleic Acid Ther. 26:210-15
71. Jackson AL, Burchard J, Schelter J, Chau BN, Cleary M, et al. 2006. Widespread siRNA "off-target" transcript silencing mediated by seed region sequence complementarity. RNA 12:1179-87
72. Jackson AL, Linsley PS. 2010. Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application. Nat. Rev. Drug Discov. 9:57-67
73. Jackson AL, Bartz SR, Schelter J, Kobayashi SV, Burchard J, et al. 2003. Expression profiling reveals off-target gene regulation by RNAi. Nat. Biotechnol. 21:635-37
74. Sheehan JP, Phan TM. 2001. Phosphorothioate oligonucleotides inhibit the intrinsic tenase complex by an allosteric mechanism. Biochemistry 40:4980-89
75. Henry SP, Giclas PC, Leeds J, PangburnM, Auletta C, et al. 1997. Activation of the alternative pathway of complement by a phosphorothioate oligonucleotide: potential mechanism of action. J. Pharmacol. Exp. Ther. 281:810-16
76. Monteith DK, Henry SP, Howard RB, Flournoy S, Levin AA, et al. 1997. Immune stimulation- A class effect of phosphorothioate oligodeoxynucleotides in rodents. Anticancer Drug Des. 12:421-32
77. Senn JJ, Burel S, Henry SP. 2005. Non-CpG-containing antisense 2-methoxyethyl oligonucleotides activate a proinflammatory response independent of Toll-like receptor 9 or myeloid differentiation factor J. Pharmacol. Exp. Ther. 314:972-79
78. Kwoh JT. 2008. An overview of the clinical safety experience of first-and second-generation antisense oligonucleotides. In Antisense Drug Technology: Principles, Strategies, and Applications, ed. ST Crooke, pp. 365-99. Boca Raton, FL: CRC Press
79. Crooke ST, Baker BF, Kwoh TJ, Cheng W, Schulz DJ, et al. 2016. Integrated safety assessment of 2-Omethoxyethyl chimeric antisense oligonucleotides in nonhuman primates and healthy human volunteers. Mol. Ther. 10:1771-82
80. Crooke ST, ed. 2008. Antisense Drug Technology: Principles, Strategies, and Applications. Boca Raton, FL: CRC Press
81. de FougerollesAR, Maraganore JM. 2007. Discovery and development of RNAi therapeutics. In Antisense Drug Technology: Principles, Strategies, and Applications, ed. ST Crooke. Boca Raton, FL: CRC Press
82. Zhou Y, Zhang C, LiangW. 2014. Development of RNAi technology for targeted therapy- A track of siRNA based agents to RNAi therapeutics. J. Control. Release 193:270-81
83. Piascik P. 1999. Fomiversen sodium approved to treat CMV retinitis. J. Am. Pharm. Assoc. 39:84-85
84. GearyRS, BakerBF, Crooke ST. 2015. Clinical and preclinical pharmacokinetics and pharmacodynamics of mipomersen (Kynamro): a second-generation antisense oligonucleotide inhibitor of apolipoprotein B. Clin. Pharmacokinet. 54:133-46
85. Raal FJ, Braamskamp MJ, Selvey SL, Sensinger CH, Kastelein JJP. 2016. Pediatric experience with mipomersen as adjunctive therapy for homozygous familial hypercholesterolemia. J. Clin. Lipidol. 10:860-69
86. Santos RD, Raal FJ, Catapano AL, Witztum JL, Steinhagen-Thiessen E, Tsimikas S. 2015. Mipomersen, an antisense oligonucleotide to apolipoprotein B-100, reduces lipoprotein(a) in various populations with hypercholesterolemia: results of 4 phase III trials. Arterioscler. Thromb. Vasc. Biol. 35:689-99
87. Yu RZ, Gunawan R, Li Z, Mittleman RS, Mahmood A, et al. 2016. No effect on QT intervals of mipomersen, a 2-O-methoxyethyl modified antisense oligonucleotide targeting ApoB-100 mRNA, in a phase I dose escalation placebo-controlled study, and confirmed by a thorough QT (tQT) study, in healthy subjects. Eur. J. Clin. Pharmacol. 72:267-75
88. Graham MJ, Lee RG, Bell TA III, Fu W, Mullick AE, et al. 2013. Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans. Circ. Res. 112:1479-90
89. Pollin TI, Damcott CM, Shen H, Ott SH, Shelton J, et al. 2008. A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection. Science 322:1702-5
90. Gaudet D, Brisson D, Tremblay K, Alexander VJ, Singleton W, et al. 2014. Targeting APOC3 in the familial chylomicronemia syndrome. N. Engl. J. Med. 371:2200-6
91. Gaudet D, Alexander VJ, Baker BF, Brisson D, Tremblay K, et al. 2015. Antisense inhibition of apolipoprotein C-III in patients with hypertriglyceridemia. N. Engl. J. Med. 373:438-47
92. Buller HR, Bethune C, Bhanot S, Gailani D, Monia BP, et al. 2015. Factor XI antisense oligonucleotide for prevention of venous thrombosis. N. Engl. J. Med. 372:232-40
93. Monteleone G, Fantini MC, Onali S, Zorzi F, Sancesario G, et al. 2012. Phase I clinical trial of Smad7 knockdown using antisense oligonucleotide in patients with active Crohn's disease. Mol. Ther. 20:870-76
94. Monteleone G, Neurath MF, Ardizzone S, Di Sabatino A, Fantini MC, et al. 2015. Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn's disease. N. Engl. J. Med. 372:1104-13
95. Yacyshyn BR, CheyWY, WedelMK, Yu RZ, Paul D, Cheung E. 2007. A randomized, double-masked, placebo-controlled study of alicaforsen, an antisense inhibitor of intercellular adhesion molecule 1, for the treatment of subjects with active Crohn's disease. Clin. Gastroenterol. Hepatol. 5:215-20
96. Miner P, Wedel M, Bane B, Bradley J. 2004.Anenema formulation of alicaforsen, an antisense inhibitor of intercellular adhesion molecule-1, in the treatment of chronic, unremitting pouchitis. Aliment. Pharmacol. Ther. 19:281-86
97. Miner PB Jr., Wedel MK, Xia S, Baker BF. 2006. Safety and efficacy of two dose formulations of alicaforsen enema compared with mesalazine enema for treatment of mild to moderate left-sided ulcerative colitis: a randomized, double-blind, active-controlled trial. Aliment. Pharmacol. Ther. 23:1403-13
98. Van Deventer SJH, Wedel MK, Baker BF, Xia S, Chuang E, Miner PB Jr. 2006. A Phase II dose ranging, double-blind, placebo-controlled study of alicaforsen enema in subjects with acute exacerbation of mild to moderate left-sided ulcerative colitis. Aliment. Pharmacol. Ther. 23:1415-25
99. Greuter T, Biedermann L, Rogler G, Sauter B, Seibold F. 2016. Alicaforsen, an antisense inhibitor of ICAM-1, as treatment for chronic refractory pouchitis after proctocolectomy: a case series. United Eur. Gastroenterol. J. 4:97-104
100. Bayever E, Iversen P, Smith S, Spinolo J, Zon G. 1992. Systemic human antisense therapy begins. Antisense Res. Dev. 2:109-10
101. Zielinski R, Chi KN. 2012. Custirsen (OGX-011): a second-generation antisense inhibitor of clusterin in development for the treatment of prostate cancer. Future Oncol. 8:1239-51
102. Hong D, Kurzrock R, Kim Y, Woessner R, Younes A, et al. 2015. AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer. Sci. Transl. Med. 7:314-185
103. Yamamoto Y, Loriot Y, Beraldi E, Zhang F, Wyatt AW, et al. 2015. Generation 2.5 antisense oligonucleotides targeting the androgen receptor and its splice variants suppress enzalutamide-resistant prostate cancer cell growth. Clin. Cancer Res. 21:1675-87
104. Grondin R, Ge P, Chen Q, Sutherland JE, Zhang Z, et al. 2015. Onset time and durability of huntingtin suppression in rhesus putamen after direct infusion of antihuntingtin siRNA. Mol. Ther. Nucleic Acids 4:e245
105. McCormack AL, Mak SK, Henderson JM, Bumcrot D, Farrer MJ, Di Monte DA. 2010.-Synuclein suppression by targeted small interfering RNA in the primate substantia nigra. PLOS ONE 5:e12122
106. Flanigan KM. 2014. Duchenne and Becker muscular dystrophies. Neurol. Clin. 32:671-88
107. Alter J, Lou F, Rabinowitz A, YinHF, Rosenfeld J, et al. 2006. Systemic delivery ofmorpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology. Nat.Med. 12:175-77
108. Aartsma-Rus A, Janson AA, Kaman WE, Bremmer-Bout M, den Dunnen JT, et al. 2003. Therapeutic antisense-induced exon skipping in cultured muscle cells from six different DMD patients. Hum. Mol. Genet. 12:907-14
109. Arechavala-Gomeza V, Graham IR, Popplewell LJ, Adams AM, Aartsma-Rus A, et al. 2007. Comparative analysis of antisense oligonucleotide sequences for targeted skipping of exon 51 during dystrophin premRNA splicing in human muscle. Hum. Gene Ther. 18:798-810
110. GoemansNM, TuliniusM, van den Akker JT, Burm BE, Ekhart PF, et al. 2011. Systemic administration of PRO051 in Duchenne's muscular dystrophy. N. Engl. J. Med. 364:1513-22
111. Mendell JR, Rodino-Klapac LR, Sahenk Z, Roush K, Bird L, et al. 2013. Eteplirsen for the treatment of Duchenne muscular dystrophy. Ann. Neurol. 74:637-47
112. Cirak S, Feng L, AnthonyK, Arechavala-Gomeza V, Torelli S, et al. 2012. Restoration of the dystrophinassociated glycoprotein complex after exon skipping therapy inDuchenne muscular dystrophy. Mol. Ther. 20:462-67
113. Mendell JR, Goemans N, Lowes LP, Alfano LN, Berry K, et al. 2016. Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy. Ann. Neurol. 79:257-71
114. Brook JD, McCurrach ME, Harley HG, Buckler AJ, Church D, et al. 1992. Molecular basis of myotnic dystrophy: expansion of a trinucleotides (CTG) repeat at the 3-end of a transcript encoding a protein kinase family member. Cell 68:799-808
115. Mankodi A, Urbinati CR, YuanQP, Moxley RT, Sansone V, et al. 2001. Muscleblind localizes to nuclear foci of aberrant RNA in myotonic dystrophy types 1 and 2. Hum. Mol. Genet. 10:2165-70
116. Mulders SA, van den BroekWJ, Wheeler TM, Croes HJ, van Kuik-Romeijn P, et al. 2009. Triplet-repeat oligonucleotide-mediated reversal of RNA toxicity in myotonic dystrophy. PNAS 106:13915-20
117. Wheeler TM, Sobczak K, Lueck JD, Osborn RJ, Lin X, et al. 2009. Reversal of RNA dominance by displacement of protein sequestered on triplet repeat RNA. Science 325:336-39
118. Wheeler TM, Leger AJ, Pandey SK, MacLeod AR, Nakamori M, et al. 2012. Targeting nuclear RNA for in vivo correction of myotonic dystrophy. Nature 488:111-15
119. Pandey SK, Wheeler TM, Justice SL, Kim A, Younis HS, et al. 2015. Identification and characterization of modified antisense oligonucleotides targeting DMPK in mice and nonhuman primates for the treatment of myotonic dystrophy type 1. J. Pharmacol. Exp. Ther. 355:329-40
120. Gertz MA, Benson MD, Dyck PJ, Grogan M, Coelho T, et al. 2015. Diagnosis, prognosis, and therapy of transthyretin amyloidosis. J. Am. Coll. Cardiol. 66:2451-66
121. Coelho T, Adams D, Silva A, Lozeron P, Hawkins PN, et al. 2013. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N. Engl. J. Med. 369:819-29
122. Suhr OB, Coelho T, Buades J, Pouget J, Conceicao I, et al. 2015. Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study. Orphanet J. Rare Dis. 10:109
123. Benson MD, Ackermann EJ, Monia BP. 2015. Treatment of transthyretin (TTR) amyloid cardiomyopathy with an antisense oligonucleotide inhibitor of TTR synthesis. Orphanet J. Rare Dis. 10:7
124. Lefebvre S, Burlet P, Liu Q, Bertrandy S, Clermont O, et al. 1997. Correlation between severity and SMN protein level in spinal muscular atrophy. Nat. Genet. 16:265-69
125. Passini MA, Bu J, Richards AM, Kinnecom C, Sardi SP, et al. 2011. Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy. Sci. Transl. Med. 3:72-18
126. Hua Y, Sahashi K, Hung G, Rigo F, Passini MA, et al. 2010. Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model. Genes Dev. 24:1634-44
127. Haché M, Swoboda KJ, Sethna N, Farrow-Gillespie A, Khandji A, et al. 2016. Intrathecal injections in children with spinal muscular atrophy: nusinersen clinical trial experience. J. Child Neurol. 31:899-906
128. Finkel RS, Chiriboga CA, Vajsar J, Day JW, Montes J, et al. 2016. Nusinersen treatment of infantile-onset spinal muscular atrophy. Lancet. In press
129. Jopling CL, Yi M, Lancaster AM, Lemon SM, Sarnow P. 2005. Modulation of hepatitis C virus RNA abundance by a liver-specific microRNA. Science 309:1577-81
130. van der Meer AJ, FaridWR, SonneveldMJ, de Ruiter PE, Boonstra A, et al. 2013. Sensitive detection of hepatocellular injury in chronic hepatitisCpatients with circulating hepatocyte-derived microRNA-122. J. Viral Hepat. 20:158-66
131. Lanford RE, Hildebrandt-Eriksen ES, Petri A, Persson R, Lindow M, et al. 2010. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 327:198-201
132. JanssenHLA, ReesinkHW, Lawitz EJ, Zeuzem S, Rodriguez-TorresM, et al. 2013. Treatment ofHCV infection by targeting microRNA. N. Engl. J. Med. 368:1685-94
133. van der Ree MH, van der Meer AJ, de Bruijne J, Maan R, van Vliet A, et al. 2014. Long-term safety and efficacy of microRNA-targeted therapy in chronic hepatitis C patients. Antiviral Res. 111:53-59
134. van der Meer AJ, de Vree ML, Stelma F, Willemse S, van der Valk M, et al. 2015. LO7: a single subcutaneous dose of 2 mg/kg or 4 mg/kg of RG-101, a GalNAc-conjugated oligonucleotide with antagonist activity against miR-122, results in significant viral load reductions in chronic hepatitis C patients. J. Hepatol. 62:S261
135. Tsimikas S, Viney NJ, Hughes SG, SingletonW, Graham MJ, et al. 2015. Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study. Lancet 386:1472-83
136. vanDeutekom JC, Janson AA, Ginjaar IB, FrankhuizenWS, Aartsma-Rus A, et al. 2007. Local dystrophin restoration with antisense oligonucleotide PRO051. N. Engl. J. Med. 357:2677-86
137. Saad F, Hotte S, North S, Eigl B, Chi K, et al. 2011. Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c. Clin. Cancer Res. 17:5765-73
138. Chi KN, Siu LL, Hirte H, Hotte SJ, Knox J, et al. 2008. A phase I study of OGX-011, a 2-methoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancer. Clin. Cancer Res. 14:833-39
139. Chi KN, Yu EY, Jacobs C, Bazov J, Kollmannsberger C, et al. 2016. A phase I dose-escalation study of apatorsen (OGX-427), an antisense inhibitor targeting heat shock protein 27 (Hsp27), in patients with castration-resistant prostate cancer and other advanced cancers. Ann. Oncol. 27:1116-22
140. Limmroth V, Barkhof F, Desem N, Diamond MP, Tachas G, ATL1102 Study Group. 2014. CD49d antisense drug ATL1102 reduces disease activity in patients with relapsing-remitting MS. Neurology 83:1780-88
141. Krug N, Hohlfeld JM, Kirsten AM, Kornmann O, Beeh KM, et al. 2015. Allergen-induced asthmatic responses modified by a GATA3-specific DNAzyme. N. Engl. J. Med. 372:1987-95
142. Gish RG, Yuen MF, Chan HL, Given BD, Lai CL, et al. 2015. Synthetic RNAi triggers and their use in chronic hepatitis B therapies with curative intent. Antivir. Res. 121:97-108